News
-
Lilly Diabetes Announces Positive Results Of Phase III Trials Of Dulaglutide In Type 2 Diabetes
10/22/2012
Eli Lilly and Company (NYSE: LLY) today announced positive top-line results of three completed Phase III AWARD trials for dulaglutide, an investigational, long-acting glucagon-like peptide 1 (GLP-1) analog being studied as a once-weekly treatment for type 2 diabetes.
-
NIH Launches Trial For Rare Degenerative Muscle Disease Treatment
9/25/2012
Researchers have launched a clinical trial to evaluate the drug candidate DEX-M74 as a treatment for a rare degenerative muscle disease, hereditary inclusion body myopathy (HIBM). National Institutes of Health scientists from the National Center for Advancing Translational Sciences (NCATS) and the National Human Genome Research Institute (NHGRI) will conduct the clinical trial at the NIH Clinical Center.
-
Lilly Announces Results From Lung Cancer Study
9/7/2012
Eli Lilly and Company (NYSE: LLY) announced today that the Phase III POINTBREAK trial did not meet its primary endpoint of improved overall survival for patients with nonsquamous non-small cell lung cancer (NSCLC) who were randomized to receive a combination of ALIMTA® (pemetrexed for injection) with bevacizumab (AVASTIN®) and carboplatin induction followed by ALIMTA plus bevacizumab maintenance–the ALIMTA arm–compared to the combination of paclitaxel with bevacizumab and carboplatin followed by bevacizumab maintenance–the paclitaxel arm.
-
Lilly Stops Phase III Development Of Pomaglumetad Methionil For The Treatment Of Schizophrenia Based On Efficacy Results
8/29/2012
Eli Lilly and Company (NYSE: LLY) announced today the decision to stop ongoing clinical studies investigating pomaglumetad methionil, also known as mGlu2/3, for the treatment of patients suffering from schizophrenia.
-
Daiichi Sankyo And Lilly Announce TRILOGY ACS Results Regarding Effient (Prasugrel) In Acute Coronary Syndrome UA/NSTEMI Patients To Be Managed Medically Without An Artery-Opening Procedure
8/26/2012
Daiichi Sankyo Company, Limited, and Eli Lilly and Company recently announced data from the TRILOGY ACS study, a phase III trial comparing prasugrel plus aspirin to clopidogrel plus aspirin in patients with unstable angina (UA) or non-ST elevation myocardial infarction (NSTEMI), who were managed medically without an arteryopening procedure.
-
Ricerca Biosciences Launches Two New Preclinical Assay Services
7/26/2012
Ricerca Biosciences, an integrated preclinical pharmaceutical contract research organization (CRO), today announced the introduction of two new state-of-the-art cellular assay services: Early Safety Screening Cytotoxicity and ImmunoSIGNAL™ Cytokine Storm Cellular Assay.
-
Camargo Uses 505(b)(2) To Fast Track Indian Products
7/24/2012
Camargo Pharmaceutical Services successfully completed five Food and Drug Administration (FDA) pre-IND meetings for 505(b)(2) products in the month of June, including successful meetings with two of India’s top 10 largest pharmaceutical companies.
-
Ampio Advances NCE001 Cancer Drug Into Preclinical Development Following Successful Recent Financing And The Granting Of Patents In USA, Canada, Europe And China
7/16/2012
Ampio Pharmaceuticals, Inc. (Nasdaq: AMPE), a biopharmaceutical company developing repurposed drugs and new molecular entities (NMEs) that treat inflammatory diseases, including osteoarthritis, diabetic macular edema (DME) and sexual dysfunction and conducting clinical trials on its four lead drugs (Ampion™, Optina™, Zertane™ & Zertane-ED™) announced today the advancement of NCE001, from its proprietary methylphenidate derivatives family of compounds, to preclinical development for the treatment of glioblastoma multiforme, renal cell carcinoma and inflammatory breast cancer following the granting of multiple composition of matter and use patents in the USA, Canada, Europe and China.
-
Lilly Announces Pomaglumetad Methionil Did Not Meet Primary Endpoint Of Clinical Study
7/11/2012
Eli Lilly and Company (NYSE: LLY) announced today negative clinical trial results from study H8Y-MC-HBBM (HBBM) investigating pomaglumetad methionil, also known as mGlu2/3, for the treatment of patients suffering an acute exacerbation of schizophrenia.
-
Ampio Contracts with Syngene to Manufacture Zertane-ED(TM), its Recently Patented Combination Drug to Treat both Premature Ejaculation (PE) and Erectile Dysfunction (ED)
7/2/2012
Ampio Pharmaceuticals, Inc. /quotes/zigman/5133505/quotes/nls/ampe AMPE +9.84% , a biopharmaceutical company conducting clinical trials on its three lead drugs (Ampion(TM), Optina(TM) & Zertane(TM)), licensing distribution of these drugs and developing additional new drugs, today announced that it is proceeding with the development plan for a combination product to treat both premature ejaculation (PE) and erectile dysfunction (ED). The positive pre-IND meeting in June with the FDA gave the company clear guidance for the two concurrent pivotal trials necessary for approval of Zertane(TM) to treat PE in the USA.